Facility manufactures cGMP bulk peptides.

Peptisyntha SA launched the expansion of its pilot-scale capacity for the production of cGMP bulk peptides based on solution phase technology at its production plant in Brussels. The expansion includes an additional pilot HPLC purification unit, an additional pilot freeze-dryer, and an additional pilot plant for the chemical synthesis of peptides. All the new units are scheduled to be fully operational in 2007.


The current development follows the recent expansion of the solid phase peptide synthesis capacity implemented by Peptisyntha, Inc. in Torrance, CA, which came on stream in 2006. Peptisyntha SA and Peptisyntha Inc. are fully owned subsidiaries of Solvay.

Previous articleEvotec and Interprotein to Develop IL-6 Inhibitors to Treat Inflammatory Diseases
Next articleImproving Pharmaceutical Productivity